Similarly, combinatorial immunotherapy with nivolumab and IFN-γ was reported in a 56-year-old diabetic patient with COVID-19 who had received dexamethasone and tocilizumab (anti-IL-6) and developed invasive pulmonary aspergillosis one week after intensive-care unit (ICU) admission, later complicated by two Mucoralean brain abscesses and ethmoidal sinusitis (55). Here, IL6 is linked to COVID-19.